Diffuse large B-cell lymphoma stage I – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:13:54 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Diffuse large B-cell lymphoma stage I – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effectiveness and Safety of Cytarabine, Tafasitamab, and Lenalidomide for Patients with Relapsed Diffuse Large B-Cell Lymphoma https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-cytarabine-tafasitamab-and-lenalidomide-for-patients-with-relapsed-diffuse-large-b-cell-lymphoma/ Wed, 29 Apr 2026 15:02:27 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-cytarabine-tafasitamab-and-lenalidomide-for-patients-with-relapsed-diffuse-large-b-cell-lymphoma/ This clinical trial is focused on studying two types of aggressive blood cancers: Diffuse Large B-Cell Lymphoma (DLBCL) and High-Grade B-Cell Lymphoma (HGBCL). These diseases originate from mature B-cells, which are a type of white blood cell. The study aims to evaluate the effectiveness and safety of starting a second-line treatment early in patients who have experienced a relapse of these lymphomas. The treatment will be guided by the levels of tumor DNA found in the blood, which is a method to detect cancer activity.

The trial involves several medications, including Cytarabine, Tafasitamab (also known as MOR00208), Lenalidomide, Dexamethasone, Cisplatin, Bendamustine Hydrochloride, Polatuzumab Vedotin (also known as RO5541077), and Rituximab. These medications are used in various forms such as solutions for infusion, injections, and capsules. Some patients may receive a placebo as part of the study. The study will monitor the overall response rate to the second-line treatment and any significant side effects that may occur.

Participants in the study will undergo regular assessments, including blood tests to measure circulating tumor DNA and imaging tests like PET-CT scans to monitor disease progression. The study will also evaluate the quality of life of participants using a specific questionnaire. The trial is expected to continue until early 2026, with the goal of improving treatment strategies for patients with these types of lymphomas.

]]>